NYSE: ENZEnzo Biochem Inc Stock
$1.09+0.00 (+0%)
Updated Apr 22, 2024
ENZ Price
$1.09
Fair Value Price
N/A
Market Cap
$55.84M
52 Week Low
$1.07
52 Week High
$2.74
P/E
1.63x
P/B
0.79x
P/S
4.97x
PEG
0.02x
Dividend Yield
N/A
Revenue
$12.81M
Earnings
$32.57M
Gross Margin
112.3%
Operating Margin
249.49%
Profit Margin
254.3%
Debt to Equity
0.4
Operating Cash Flow
-$44M
Beta
0.46
Next Earnings
Jun 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ENZ Overview
Enzo Biochem, Inc. manufactures and sells diagnostic and research products based on genetic engineering, biotechnology, and molecular biology to clinical laboratories, researchers, and physicians in the U.S. and internationally. Offerings include proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits used for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. Enzo Biochem was founded in 1976 and is headquartered in Farmingdale, NY.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENZ ($1.09) is trading below its intrinsic value of $23.75, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENZ is good value based on its earnings relative to its share price (1.63x), compared to the US market average (41x)
P/E vs Market Valuation
ENZ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ENZ due diligence checks available for Premium users.
Be the first to know about important ENZ news, forecast changes, insider trades & much more!
ENZ News
Valuation
ENZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.63x
Industry
36.48x
Market
41x
ENZ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ENZ is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ENZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.79x
Industry
4.05x
ENZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENZ price to earnings growth (PEG)
For valuing profitable companies with growth potential
ENZ is good value based... subscribe to Premium to read more.
PEG Value Valuation
ENZ's financial health
Profit margin
Revenue
$8.6M
Net Income
-$3.1M
Profit Margin
-35.8%
ENZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ENZ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$99.1M
Liabilities
$28.3M
Debt to equity
0.4
ENZ's short-term assets ($80.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENZ's short-term assets ($80.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENZ's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ENZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.9M
Investing
-$25.0k
Financing
-$22.0k
ENZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENZ vs Diagnostic & Research Stocks
Enzo Biochem Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.